The Trump administration is reinstating a policy that would allow immigration officers to deny green cards to applicants who use public benefits such as Medicaid, food stamps, housing vouchers, or other safety net programs. The rule reverses a 2022 Biden-era policy and governs how officials apply the 'public charge' test in immigration decisions.
Starting July 1, 2026, Medicare will cover select GLP-1 weight loss medications for approximately $50 through a Trump administration pilot program, marking the first time the federal program has covered obesity drugs. The 18-month initiative raises concerns about potential drug shortages.
Family planning and health organizations in Pennsylvania have filed a lawsuit alleging that a new Trump administration policy could delay or deny federal funding to providers serving tens of thousands of patients across the state.
The Trump administration finalized major changes to Affordable Care Act exchanges, including significantly greater access to catastrophic health plans with high deductibles, raising concerns among insurance experts and healthcare stakeholders about coverage adequacy.
The U.S. Supreme Court on Thursday maintained access to the abortion pill mifepristone through telehealth and mail delivery, setting aside lower court restrictions while litigation over the drug continues. Mifepristone is used in more than 60% of U.S. abortions.
Hundreds of hospitals nationwide face potential closure following Medicaid cuts from the One Big Beautiful Bill Act, prompting state lawmakers to explore emergency loans and financial assistance programs to prevent healthcare access disruptions.
The Supreme Court heard oral arguments on a case involving 'skinny labeling' practices that have significant implications for generic drug availability and access, with justices appearing to signal the practice may survive legal challenge.
The Centers for Medicare & Medicaid Services and FDA announced a new pathway to streamline Medicare coverage for breakthrough medical devices, cutting red tape and providing predictability for device manufacturers and faster patient access to life-changing technologies.
